Ireland
--:--IST
Priya Life Science Compound trial record
Compound · clinical trials

Tioguanin clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 8 trials in our Australia, Canada, Israel, Mexico, Germany, Italy, Switzerland, Austria, Czechia, France, Netherlands, Belgium and Sweden registers that name Tioguanin as an intervention. Synced 17 Nov 2026
8Current trials
3Recruiting now
3Lead sponsors
13Country registers
At a glance

Tioguanin is named as an intervention in 8 current clinical trials in our Australia, Canada, Israel, Mexico, Germany, Italy, Switzerland, Austria, Czechia, France, Netherlands, Belgium and Sweden registers. 3 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is National Cancer Institute (NCI) (4). The most-studied condition is B Acute Lymphoblastic Leukemia.

What health systems spend on Tioguanin

All medicines →
ENNHS England
£458
15 items dispensed, Sep 2025 to Aug 2026
-64% on the previous 12 months
Net ingredient cost, community prescriptions
USUS Medicaid
No single-ingredient product reimbursed by Medicaid in 2025
Amount Medicaid reimbursed, before rebates

From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.

Patient leaflets for Tioguanin

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

  • IE
    Ireland: 1 product on the HPRA list
    Each product record links to the HPRA, which publishes the leaflet and SmPC.
  • UK
    United Kingdom: Search MHRA Products
    Patient information leaflets and SmPCs for UK-licensed products.
  • US
    United States: Search DailyMed
    FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

  • Recruiting338%
  • Active, closed563%

Trials by phase

  • Phase 3788%
  • Phase 2113%
01

Clinical trials of Tioguanin

8 trials
StudyPhaseStatusLead sponsorRegisters
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
NCT03643276 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Pediatric
Phase 3 Recruiting Martin Schrappe Germany, Italy, Switzerland, Austria, Czechia, Australia, Israel
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
NCT03959085 · ClinicalTrials.gov ↗ · B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia
Phase 3 Recruiting Children's Oncology Group Canada, Mexico, Australia, Israel
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
NCT06124157 · ClinicalTrials.gov ↗ · B Acute Lymphoblastic Leukemia
Phase 2 Recruiting National Cancer Institute (NCI) Canada, Mexico, Australia
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
NCT02101853 · ClinicalTrials.gov ↗ · Recurrent B Acute Lymphoblastic Leukemia
Phase 3 Active, closed National Cancer Institute (NCI) Canada, Australia, Israel
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
NCT02112916 · ClinicalTrials.gov ↗ · Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma
Phase 3 Active, closed National Cancer Institute (NCI) Canada, Mexico, Australia, Israel
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
NCT02521493 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Down Syndrome, Myelodysplastic Syndrome
Phase 3 Active, closed Children's Oncology Group Canada, Mexico, Australia
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT03007147 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
Phase 3 Active, closed Children's Oncology Group Germany, France, Italy, Netherlands, Belgium, Sweden, Switzerland, Austria, Czechia, Canada, Mexico, Australia, Israel
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
NCT03914625 · ClinicalTrials.gov ↗ · B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome
Phase 3 Active, closed National Cancer Institute (NCI) Canada, Mexico, Australia, Israel

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Tioguanin across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

1 single-substance product containing Tioguanin on the HPRA medicines list.

  • Lanvis 40mg TabletsAspen Pharma Trading Limited · PA1691/006/001 · Not marketed
All 1 Irish product →

Supply shortages

No entry for Tioguanin in the EMA, FDA or German BfArM shortage lists we track.

03

Conditions studied with Tioguanin

16 conditions
B Acute Lymphoblastic Leukemia4Mixed Phenotype Acute Leukemia2Down Syndrome2B Lymphoblastic Lymphoma2Acute Lymphoblastic Leukemia, Pediatric1Acute Lymphoblastic Leukemia1T Acute Lymphoblastic Leukemia1Acute Myeloid Leukemia1Myelodysplastic Syndrome1Myeloid Leukemia Associated With Down Syndrome1Recurrent B Acute Lymphoblastic Leukemia1Adult T Acute Lymphoblastic Leukemia1
All 16 conditions
Condition (as registered)Trials
B Acute Lymphoblastic Leukemia4
Mixed Phenotype Acute Leukemia2
Down Syndrome2
B Lymphoblastic Lymphoma2
Acute Lymphoblastic Leukemia, Pediatric1
Acute Lymphoblastic Leukemia1
T Acute Lymphoblastic Leukemia1
Acute Myeloid Leukemia1
Myelodysplastic Syndrome1
Myeloid Leukemia Associated With Down Syndrome1
Recurrent B Acute Lymphoblastic Leukemia1
Adult T Acute Lymphoblastic Leukemia1
Ann Arbor Stage II Adult Lymphoblastic Lymphoma1
Ann Arbor Stage II Childhood Lymphoblastic Lymphoma1
Ann Arbor Stage III Adult Lymphoblastic Lymphoma1
Central Nervous System Leukemia1
06

Related compounds

07

Questions about Tioguanin trials

How many clinical trials are testing Tioguanin?

8 current trials in our Australia, Canada, Israel, Mexico, Germany, Italy, Switzerland, Austria, Czechia, France, Netherlands, Belgium and Sweden registers name Tioguanin as a drug or biological intervention, as of the registry sync on 17 November 2026. Completed and withdrawn studies are not counted.

Are Tioguanin trials recruiting patients?

Yes. 3 of the 8 trials are recruiting: 3 with sites in Australia, 2 with sites in Canada, 2 with sites in Israel, 2 with sites in Mexico, 1 with sites in Germany, 1 with sites in Italy, 1 with sites in Switzerland, 1 with sites in Austria and 1 with sites in Czechia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Tioguanin clinical trials?

National Cancer Institute (NCI) (4), Children's Oncology Group (3) and Martin Schrappe (1). The number in brackets is how many trials each organisation leads.

Is Tioguanin licensed in Ireland?

Yes. The HPRA medicines list includes 1 single-substance product containing Tioguanin, for example Lanvis 40mg Tablets (Aspen Pharma Trading Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Tioguanin shortage?

Not in the lists we track: Tioguanin has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Tioguanin works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tioguanin works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tioguanin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 17 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.